Alnylam Pharmaceuticals sees stake shifts as Q1 revenue beats estimates but misses on EPS.

Meridian Financial and Perpetual Ltd reduced their stakes in Alnylam Pharmaceuticals, while Allspring Global Investments Holdings purchased shares. Alnylam's stock is rated "Moderate Buy" with a price target of $337.91. The company reported a Q1 revenue of $594.19 million, exceeding expectations, but missed EPS estimates. Alnylam's CEO also sold a significant portion of her shares recently.